/Bristol-Myers%20Squibb%20Co_%20logo%20on%20building-by%20tatu%20Campelo%20via%20iStock.jpg)
Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products. With a market cap of $102.2 billion, the company focuses on products and experimental therapies address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
Shares of this biopharma giant have outperformed the broader market over the past year. BMY has gained 12.2% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 11.7%. However, in 2025, BMY stock is down 12.3%, compared to the SPX’s 4.7% decline on a YTD basis.